{
  "docId": "019de075-a698-70b1-b3ba-29e176396a9c",
  "docSlug": "63ec8e773c9b43e7b033b64167026114",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 52,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 6,
  "notes": "Includes a footer citing FDA approval precedents for similar patient population sizes.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/11",
  "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c",
  "deckJsonHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c.json",
  "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.02,
        "x": 0.21,
        "y": 0.32
      },
      "kind": "diagram",
      "text": "Arrow indicating progression from Phase 1b/2a to Phase 2a",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "820d2ca9-1f53-423d-b352-bb85e04ebf9a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "FDA approval precedents include: Abecma/BMS (100 patients in efficacy results population, FDA approved 2021); Carvykti/J&J (97 patients in efficacy results population, FDA approved 2022); Elrexfio/Pfizer (97 patients in efficacy results population, FDA approved 2023)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "911282a3-16e8-437c-be8c-f23cd76eaaca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.96,
        "x": 0.02,
        "y": 0.2
      },
      "kind": "table",
      "text": "Target Indication, Trial, Status columns with rows for AL Amyloidosis and Multiple Myeloma",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aadc51ca-20ef-4e0d-9b82-f71dde9175e6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.02,
        "y": 0.05
      },
      "kind": "title",
      "text": "NXC-201 Clinical Development Plan",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a1011025-39f4-443e-9f01-c2b9bc68fefb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "90e96491-444e-4255-a5de-9ae9a1b4bc6c",
      "evidence": "The slide contains a table with data on Target Indication, Trial, Status for AL Amyloidosis and Multiple Myeloma.",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "authority-citation",
      "slug": null,
      "matchId": "6bdcfc1d-00de-4ad3-b66f-d988eb8832a4",
      "evidence": "Footer cites FDA approval precedents to validate clinical trial design",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 23,
      "from": 10,
      "beatId": "b4eaa88f-5d19-4a97-bcad-d3506fb7e4a8",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Presentation of NXC-201 and IMX-110 as innovative therapies",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}